Noruxol - antiseptic dermatological ointment for sores and decubitus ulcers 30g

Product Description

Noruxol Dermatological Ointment

Composition:

1 g of Noruxol contains: Active ingredient: 0.52 ÷ 3.75 mg of collagenase N containing: • Clostridiopeptidase A not less than 1.2 Units • Associated proteases not less than 0.24 Units

Excipients

Liquid paraffin, white petrolatum.

Therapeutic indications

Enzymatic cleansing of necrotic wounds, including leg ulcers and pressure ulcers.

Contraindications

Hypersensitivity to the active substance (collagenase) or to any of the excipients of the ointment.

Dosage

To ensure successful enzymatic treatment of skin lesions with Noruxol, there must be sufficient moisture in the wound area. Therefore, in dry wounds, the base of the wound should be moistened with physiological saline solution (0.9% NaCl) or other solutions well tolerated by the tissue (e.g. glucose). Dry and hard crusts should first be softened by applying a moist dressing. A layer of Noruxol approximately 2 mm thick should be applied with the dressing or directly to the slightly moistened area once a day. Cover the wound surface to ensure contact. It is not necessary to apply a generous layer of product to the wound as this does not promote the progress of cleansing. Generally, changing the dressing once a day is sufficient unless otherwise advised by your doctor.

Warnings and Precautions

Repeated use of topical products may give rise to sensitization phenomena. Whenever an infection is present, appropriate antibiotic treatment should be considered. Chloramphenicol, neomycin, framycetin, bacitracin, gentamicin, polymyxin B, and macrolides—for example, erythromycin—have been shown to be compatible with collagenase. Contact with eyes and mucous membranes should be avoided. In patients with severe burns, Noruxol should be used on the advice and under the supervision of a specialist. In diabetic patients, dry gangrene should be moistened, taking care to avoid its transformation into wet gangrene. If no reduction in necrotic content is observed within 14 days of starting therapy with Noruxol, it is recommended to discontinue treatment and adopt alternative debridement methods. After the first opening, the product can no longer be considered sterile. Any residue, therefore, should not be used but must be discarded.

Interactions

Noruxol should not be used in the presence of antiseptics, heavy metals, detergents, and soaps, as they inhibit its enzymatic activity. However, products containing silver and silver sulfadiazine can be used with Noruxol without altering its enzymatic activity. Tyrothricin, gramicidin, and tetracyclines should not be used topically with Noruxol.

Side effects

Side effects may include local pain, itching, burning, and erythema. Discontinuation of therapy should be considered if reactions are severe.

Pregnancy and breastfeeding

Although no teratogenic effects have been observed, NORUXOL should be administered during the first three months of pregnancy only when strictly indicated. Since collagenase does not enter the systemic circulation, it is unlikely that it will be excreted in breast milk.